Contact form
Submitted by admin on
Copaxone ®
The first innovative drug to be developed in Israel and to receive FDA approval, Copaxone® is a unique multiple sclerosis immunomodulator: the first and only non-interferon agent for the treatment of relapsing-remitting multiple sclerosis. Copaxone® is licensed to Teva Pharmaceuticals Ltd.
Erbitux®
An antibody based therapy presenting synergism with conventional chemotherapy. The synergistic effect was invented at the Weizmann Institute. Erbitux was developed by ImClone Systems and approved by the FDA in 2001.
NanoLub TM
NanoLubTM, is the world’s first commercial solid lubricant based on spherical inorganic nanoparticles. NanoLubTM reduces friction & wear significantly better than conventional lubricants. Licensed to Nanomaterials Inc.
Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education.
Pages
